In a recent Nature paper, researchers traced a quiet chain of cause within the brains of mice that model Angelman syndrome. An enzyme that is ordinarily harmless, ASNS, gathers in neurons and keeps them in a state of lingering stress, and that persistent signal appears to hold back the growth of the brain. The genetic origin of the condition was already known; what this work adds is a sense of the intermediate步 where a familiar cause becomes a lasting effect. Whether the same thread can be loosened in human patients remains a question the mice cannot yet answer.
Excess Enzyme ASNS Keeps Neurons in Chronic Stress, Stunting Brain Growth in Angelman Syndrome Mice
An ordinarily harmless enzyme, building up, holds neurons in chronic stress
Mark
So what did the researchers actually find?
Mimi
That an enzyme called ASNS, usually harmless, builds up in the neurons of mice modelling Angelman syndrome. The buildup keeps the neurons under persistent stress, and brain growth is stunted.
Mark
Why does it matter if the genetic cause is already known?
Mimi
Because the genetic cause doesn't tell you the steps between the gene and the traits. This points to stress signalling as one of those steps, and it's tied to several features of the syndrome.
Luke
I'd slow down on the word 'underlies.' The Nature title uses it, but what do we know about how much of the syndrome this explains?
Mimi
Fair. The reporting says several features, not all. It doesn't give a proportion.
Mark
One headline talks about restoring brain growth. Is that established?
Luke
Not in anything I can see here. That's a headline framing. The material describes the mechanism, and says nothing about a completed treatment, in mice or people.
Mimi
And the forward look is explicit: whether reducing ASNS helps people is untested.
Mark
So what's solid?
Luke
That it's a mouse study, published in Nature, linking excess ASNS to stress signalling and stunted growth. Anything about patients is still a question, not a result.
O Pulso
- A normally harmless enzyme, ASNS, is piling up in the neurons of mice modelling Angelman syndrome and quietly stunting brain growth.
- Persistent stress signals inside brain cells are now suspected of driving several features of the condition, not just its genetic root.
- Researchers are working backward from the genetic cause to pin down the specific downstream process that keeps neurons under strain.
- The science is still confined to mouse models, and no trial has yet tested whether lowering ASNS activity would help people with Angelman syndrome.
In a recent Nature paper, researchers traced a quiet chain of cause within the brains of mice that model Angelman syndrome. An enzyme that is ordinarily harmless, ASNS, gathers in neurons and keeps them in a state of lingering stress, and that persistent signal appears to hold back the growth of the brain. The genetic origin of the condition was already known; what this work adds is a sense of the intermediate步 where a familiar cause becomes a lasting effect. Whether the same thread can be loosened in human patients remains a question the mice cannot yet answer.
A paper in Nature this week reports that a normally harmless enzyme called ASNS builds up in the neurons of mice engineered to model Angelman syndrome. Its accumulation keeps those cells in a state of persistent stress, and that stress appears to stunt brain growth.
Science outlets framed the result in several ways. Neuroscience News suggested it points toward restoring brain growth, while Bioengineer.org and Medical Xpress emphasised the link between neuronal stress and the condition's features. The Nature paper's own title is more formal, describing persistent neuronal stress signalling as underlying the syndrome's traits.
The central idea is about mechanism. Angelman syndrome has a known genetic cause, but this work looks at what happens after it. Persistent stress signalling, driven by too much ASNS, appears to account for several features of the syndrome. In these mice, the enzyme is ordinarily benign, and only its buildup turns it into a problem.
That specificity matters. A stress pathway tied to one enzyme is a more concrete target than a general description of what goes wrong.
The limits are clear, however. All of the evidence comes from mouse models, and no test of lowering ASNS in people has been reported. Mouse and human brains differ, so a mechanism in one does not guarantee a treatment in the other.
What comes next is confirmation by other laboratories, and whether researchers move from explaining the mechanism to testing whether reducing the enzyme changes outcomes. For now, the work offers a clearer account of stunted growth in these mice and a candidate target not yet tried in people.
A paper in Nature this week reports that a normally harmless enzyme called ASNS accumulates in the neurons of mice engineered to model Angelman syndrome, and that its buildup keeps those cells in a state of persistent stress that stunts brain growth.
The finding was picked up by several outlets that cover science. Neuroscience News headlined it as a way of restoring brain growth in Angelman syndrome. Bioengineer.org described excess ASNS as linking neuronal stress to features of the condition in mice. Medical Xpress and WashU Medicine each framed it as the buildup of a common enzyme stunting brain growth. The Nature paper's own title puts the mechanism more formally: persistent neuronal stress signalling underlies Angelman syndrome phenotypes.
The point the researchers make is about mechanism. Angelman syndrome has a known genetic cause, but the reporting indicates the new work looks at what happens downstream of it. According to the findings, persistent stress signalling inside neurons, driven by too much ASNS, helps account for several features of the syndrome, not only the underlying genetic change. In the mouse models, the enzyme is described as ordinarily benign. Its accumulation is what appears to turn it into a problem, by holding neurons in chronic stress and limiting how much the brain grows.
That framing matters because it identifies a specific, nameable process between the genetic cause and the observable traits. A stress pathway driven by one enzyme is, in principle, a more concrete thing to study than a general description of what goes wrong. The headline from Neuroscience News, which speaks of restoring brain growth, reflects the idea that the stunting may not be fixed once and for all but tied to an ongoing signal.
The limits are plain, though. Everything reported so far comes from mouse models. The source material does not describe any test of lowering ASNS activity in people with Angelman syndrome, and whether doing so would help them remains untested. Mouse brains and human brains differ, and a mechanism that explains stunted growth in one model does not by itself show a treatment will work in patients.
What to watch for next is whether other laboratories confirm the ASNS finding, and whether anyone moves from explaining the mechanism to testing whether reducing the enzyme's activity changes outcomes. For now, the work offers a clearer account of why growth is stunted in these mice, and a candidate target that has not yet been tried in people.
Citações Notáveis
Persistent neuronal stress signalling underlies Angelman syndrome phenotypes.— Title of the Nature paper
Quer a matéria completa?
Leia o original em Google News ↗
Health & Medicine